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RESUMO 
 
Os microcarcinomas papilares da tiróide (mPTC) são definidos como carcinomas 
papilares da tiróide (PTC) que medem 1 centímetro ou menos na sua máxima dimensão. 
Estes tumores são muito comuns e são, muitas vezes, encontrados incidentalmente. As 
taxas de incidência dos mPTC têm aumentado constantemente em todo o mundo devido 
à melhoria dos métodos de diagnóstico. Na maioria dos casos, os mPTC têm um 
comportamento benigno com percurso indolente e um prognóstico excelente. No entanto, 
alguns casos apresentam características de agressividade e podem requerer tratamentos 
mais agressivos. A estratégia terapêutica padrão para estes tumores continua a ser um 
tema controverso. Com o objectivo de prever os casos que vão causar doença 
significativa muitos estudos têm tentado associar marcadores de mau prognóstico com 
alterações genéticas neste tipo de tumor.  
Os PTC frequentemente têm alterações genéticas que levam à activação da via 
de sinalização mitogen-activated protein kinase (MAPK). Essas alterações incluem as 
mutações pontuais do proto-oncogene B-Raf (BRAF) e RAS Viral Oncogene Homolog 
(RAS) e o rearranjo RET/PTC. As mutações envolvendo um destes genes são 
encontradas em 70% dos PTC e raramente se sobrepõe no mesmo tumor. Recentemente foram 
encontradas mutações no promotor do gene telomerase reverse transcriptase (TERT), com 
uma prevalência de 10% em cancro da tiróide. 
O objectivo principal deste trabalho era avaliar o perfil genético dos mPTC. Para 
isso, planeámos avaliar a prevalência das mutações do BRAF (exão 15, região do codão 
600), NRAS (exão 3, região do codão 61) e promotor do TERT, numa série de mPTC. 
Também planeámos investigar as possíveis associações entre estas alterações genéticas 
com características clinicopatológicas clássicas. 
A caracterização genética desta série revelou a ausência de mutações no gene 
NRAS. Foi também possível ver, como esperado, um grande número de casos 
multifocais, incidentais e um maior número de casos a afectar as mulheres do que os 
homens. Curiosamente, a arquitectura folicular foi predominante nesta série e isso poderá 
estar relacionado com as características de agressividade destes casos. O trabalho 
apresentado nesta tese é parte de um trabalho que ainda está a decorrer, com mais 
casos para serem analisados em relação às alterações genéticas do BRAF, NRAS e 
promotor do TERT. Os resultados que vierem desta análise futura são de grande 
importância para melhor perceber a relação entre as alterações genéticas e o resultado 
clínico neste tipo de tumores. Continua por ser encontrado um marcador que consiga 
distinguir quais dos mPTC vão de facto apresentar um mau prognóstico e requerer uma 
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abordagem mais radical para os tratar. Para além disso, como observado em alguns 
países, o aumento dos casos de detecção destas pequenas lesões representa um grande 
encargo económico. Assim, é fundamental identificar marcadores que nos permitam 
reconhecer os casos que vão causar doença significativa para que uma atitude 
terapêutica mais adequada seja tomada. 
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ABSTRACT 
  
Papillary microcarcinoma of the thyroid (mPTC) is defined as a papillary thyroid 
carcinoma (PTC) that measures 1 centimeter or less in its maximum dimension. These 
tumors are very common and are often found incidentally. mPTC incidence rates have 
been steadily increasing all over the world due to improvement of diagnostic methods. In 
most of the cases, mPTC has a benign behaviour with an indolent course and excellent 
prognosis. However, some have aggressive features and may require aggressive 
treatment. The standard therapeutic approach for these tumors remains controversial. 
With the purpose of predicting those that will cause significant disease, many studies have 
been trying to associate poor prognostic markers with genetic alterations in this type of 
cancer.  
PTC frequently has genetic alterations leading to the activation of the mitogen-
activated protein kinase (MAPK) signalling pathway. Those include B-Raf Proto-
Oncogene, Serine/Threonine Kinase (BRAF) and RAS Viral Oncogene Homolog (RAS) 
point mutations and RET/PTC rearrangements. Mutations involving one of these genes 
are found in >70% of PTC and they rarely overlap in the same tumor. Recently, mutations 
in telomerase reverse transcriptase (TERT) gene promoter were found in thyroid cancer 
with an overall prevalence of near 10%. 
The general aim of this work was to evaluate the mPTC genetic profile. In order to 
do that, we intended to evaluate the prevalence of BRAF (exon 15, codon 600 region), 
NRAS (exon 3, codon 61 region) and TERT promoter mutations in a series of mPTC. We 
also intended to investigate possible associations of those genetic alterations with 
classical clinicopathological features. 
The genetic characterization of this series revealed no mutations in NRAS gene. It 
was also possible to see a high number of multifocal, incidental and female cases, as 
expected. Interestingly, follicular architecture was predominant in this series and that can 
be related with the aggressive features of these cases. The work presented on this thesis 
is still part of an ongoing work with more cases to be analysed for genetic alterations in 
BRAF, NRAS and TERT promoter. The results arising from this future analysis are of 
major importance for better understanding the relationship between genetic alterations 
and clinical outcome in this type of tumors. It remains to be found a marker that could 
distinguish which of these mPTC will indeed present a worse prognosis and will require a 
more radical approach in order to treat them. Additional, as observed in some countries, 
the increased detection of these small lesions represents an economic burden. Therefore, 
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we aim to identify those that will cause significant disease so an aggressive therapeutic 
approach can be taken.  
XIII 
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Figure 1 - Macro and microscopic structure of the thyroid gland. The gland is located 
in the lower anterior neck across the front of the trachea. A single layer of follicular cells 
outlines each of the basic units, the follicle, and colloid is present in their lumen. In the 
interfollicle space there can be seen blood vessels and a couple of C cells grouped 
together (Boron et al. (2012) Section VIII: The endocrine system, in Medical Physiology: A 
cellular and molecular approach). 
Figure 2 - Synthesis of thyroid hormones as seen on an individual thyroid follicular 
cell - Thyroglobulin is synthesized in the endoplasmic reticulum and secreted into the 
lumen of thyroid follicle by exocytosis. At the same time, iodide (I-) is brought into the cell 
by a sodium-iodide (Na+/I-) symporter. This iodide is brought out of the follicular cells and 
into the lumen by the transporter pendrin. In the lumen, iodide (I-) is oxidized to iodine (I0) 
by an enzyme called thyroid peroxidase. Iodine (I0) is very reactive and iodinates the 
thyroglobulin at tyrosyl residues. Adjacent tyrosyl residues are paired together. The entire 
complex re-enters the follicular cell by endocytosis. Proteolysis liberates thyroxine and 
triiodothyronine molecules, which enter the bloodstream [1] (Häggström et al (2014.) 
Medical gallery of Mikael Häggström 2014, in Wikiversity Journal of Medicine). 
Figure 3 – Papillary thyroid carcinoma histologic features (Schularick et al (2013) 
Pathology of papillary thyroid carcinoma, in Iowa Head and Neck protocols). 
Figure 4 – Schematic representation of the MAPK signaling pathway. Physiologically, 
binding of growth factors to receptor TKs, results in receptor dimerization and activation 
via autophosphorylation of tyrosine residues in the intracellular domain. The activated 
receptor, through a series of adaptor proteins, leads to activation of RAS located at the 
inner face of the plasma membrane by substitution of GDP with GTP. The GTP-bound 
form of RAS binds to and recruits RAF proteins, mainly BRAF in thyroid follicular cells, to 
the plasma membrane. Activated BRAF is now able to phosphorylate and activate the 
MEK, which in turn phosphorylates and activates the ERK. Once activated, ERK 
phosphorylates cytoplasmic proteins and translocates into the nucleus, in which it 
regulates transcription of the genes involved in cell differentiation, proliferation, and 
survival. Alterations of this pathway in thyroid cancer can occur at different levels as a 
result of point mutations or rearrangement involving the RET, RAS and BRAF genes [2] 
(Ciampi et al. (2007) RET/PTC Rearrangements and BRAF mutations in thyroid 
tumorigenesis, Endocrinology). 
Figure 5 – Representative results of an agaroses gel electrophoresis for the PCR of 
NRAS codon 61 region, with a size of about 119 basepairs (1-DNA ladder; 2 & 3-
negative control; 5 to 11-Positive case for amplification of NRAS). 
Figure 6 – Wild-type representative results obtained through sequencing analysis 
of NRAS codon 61 (bounded by 2 red lines) region, primer forward. 
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INTRODUCTION 
 
 
THE THYROID GLAND 
 
Thyroid anatomy 
The thyroid gland (Figure 1) is composed of two lobes connected by an isthmus 
and is located in the trachea approximately at the level of the second tracheal ring [3]. 
Each lobe is about 4 cm in length and 2 cm thickness and resides in a bed between the 
trachea and larynx medially and the carotid sheath and the sternocleidomastoid muscles 
laterally [3, 4]. The strap muscles are anterior to the thyroid lobes, and the parathyroid 
glands and recurrent laryngeal nerves are associated with the posterior surface of each 
lobe [3]. The gland is enveloped by the deep cervical fascia and is attached firmly to the 
trachea by the ligament of Berry [3]. Weighing approximately 20g, is one of the largest 
endocrine glands in the body and receives a high blood supply from the superior and 
inferior thyroid arteries [4]. A rich plexus of lymph vessels is in close proximity of the 
individual follicles, but no unique role in the thyroid function has been assigned to the 
system [5]. The major, if not only, secretory pathway for thyroid hormone is through the 
venous drainage of the thyroid rather than through the lymphatics, nonetheless 
thyroglobulin is mainly secreted in the lymph [5]. 
 
Figure 1 - Macro and microscopic structure of the thyroid gland. The gland is located in the lower anterior 
neck across the front of the trachea. A single layer of follicular cells outlines each of the basic units, the follicle, 
and colloid is present in their lumen. In the interfollicle space there can be seen blood vessels and a couple of 
C cells grouped together (Boron et al. (2012) Section VIII: The endocrine system, in Medical Physiology: A 
cellular and molecular approach). 
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The adult thyroid is composed of follicles, or acini, that are considered as the 
primary and secretory units of the organ. The cells of the follicles participate in hormone 
synthesis: tri-iodothyronine (T3) and tetra-iodothyronine or thyroxine (T4); and the lumina 
are the storage depots. In the normal adult gland, the follicles are roughly spherical and 
vary considerably in size with an average diameter of 300 microns. Their walls consist of a 
continuous epithelium one cell deep, the parenchyma of the thyroid. Within the follicle and 
filling its lumen is the homogeneous colloid, composed of a mixture of proteins, principally 
thyroglobulin [5].  
In addition to the acinar cells, there are individual cells or small groups of cells 
which may appear as clusters between follicles. These light cells, or C-cells, are a distinct 
category that was believed to be derived from the neural crest via the ultimobranchial 
body; recently, the neural crest-derived theory has been challenged and an endoderm 
stem cell-derived differentiation has been proposed [6]. These cells secrete calcitonin in 
response to an increase in serum calcium [5]. 
Outside the follicles other types of cells populate the thyroid: the endothelial cells, 
the fibroblasts and immune cells [5]. 
 
 Thyroid Physiology 
 
The synthesis of thyroid hormones (Figure 2) is a complex process that occurs 
between the follicle cells and the colloid. Iodide is actively transported by the Sodium-
Iodide (Na+/I-) symporter (NIS) against an electrical gradient at the basal membrane of 
follicular cells [5]. There, it is oxidized to active iodine in a reaction catalysed by thyroid 
peroxidase (TPO) [4]. At the apical-colloid interface, iodine is immediately incorporated 
into the tyrosine residues of thyroglobulin molecules [4]. Thyroglobulin is a large 
glycoprotein synthesized in follicular cells and about one quarter of its residues can be 
iodinated [4]. Once iodinated, thyroglobulin is taken up into the colloid of the follicle where 
a coupling reaction, catalysed by TPO, between pairs of iodinated tyrosine molecules 
occurs [4]. The coupling of two tyrosine residues each iodinated at two positions (di-
iodotyrosine, DIT) produces T4, whereas the combination of DIT with mono-iodotyrosine 
produces T3 [4]. Thyroid hormones are therefore stored in this state and are only released 
when the thyroglobulin molecule is uptake into the follicular cells [4]. Secretion of thyroid 
hormones is stimulated by the thyroid stimulating hormone (TSH), also called thyrotropin, 
and  requires endocytosis of thyroglobulin, its hydrolysis and release of thyroid hormones 
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from the cell [5]. The active uptake of iodide appears to be the main control point for 
hormone synthesis and is stimulated by TSH [4]. 
 
Figure 2 - Synthesis of thyroid hormones as seen on an individual thyroid follicular cell - 
Thyroglobulin is synthesized in the endoplasmic reticulum and secreted into the lumen of thyroid 
follicle by exocytosis. At the same time, iodide (I
-
) is brought into the cell by a sodium-iodide (Na
+
/I
-
) symporter. 
This iodide is brought out of the follicular cells and into the lumen by the transporter pendrin. In the lumen, 
iodide (I
-
) is oxidized to iodine (I
0
) by an enzyme called thyroid peroxidase. Iodine (I
0
) is very reactive and 
iodinates the thyroglobulin at tyrosyl residues. Adjacent tyrosyl residues are paired together. The entire 
complex re-enters the follicular cell by endocytosis. Proteolysis liberates thyroxine and triiodothyronine 
molecules, which enter the bloodstream [1] (Häggström et al (2014.) Medical gallery of Mikael Häggström 
2014, in Wikiversity Journal of Medicine). 
 
 
THYROID TUMORS  
Thyroid carcinoma represents a very heterogeneous disease being composed of 
distinct and clinically different entities, namely differentiated thyroid carcinoma (DTC), 
poorly differentiated thyroid cancer (PDTC), anaplastic thyroid carcinoma (ATC), and 
medullary thyroid carcinoma (MTC) [7] [8]. Based in tumour morphology DTC can be 
further stratified in papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) 
[9]. ATC, arising from follicular cells comprehend the rarest but the most lethal thyroid 
cancer affecting elderly patients and being characterized by an high aggressiveness and a 
very poor prognosis [10]. Poorly differentiated thyroid carcinomas and ATC are believed to 
mainly develop as a result of dedifferentiation of a well-differentiated papillary or follicular 
thyroid carcinoma [7]. MTC represents a neuroendocrine tumor derived from the 
parafollicular C-cells of the thyroid gland and is irresponsive to radioiodine therapy (RAI) 
[8] [11]. 
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Presentation, diagnosis and treatment 
 
At the time of initial assessment, most patients with thyroid cancer have a palpable 
neck mass, either a primary intrathyroidal tumor or metastatic regional lymphadenopathy 
[12]. In some patients, however, the tumor may be clinically occult, and the impalpable 
lesion may first be recognised on a high-resolution neck imagiological study or at the time 
of surgical intervention for presumed benign thyroid disease [12]. Therefore, thyroid 
ultrasonography is the first imaging study to perform in any patient with a possible thyroid 
malignancy [13]. After identification of a lesion by ultrasound imaging, fine-needle 
aspiration biopsy (FNAB) is performed [13]. FNAB is considered the best first-line 
diagnostic procedure for a thyroid nodule, being a minimally invasive procedure, safe and 
with near 80% of sensitivity and near 100% of specificity [14, 15]. FNAB will allow 
cytological or histological analysis for diagnostic confirmation [12]. Before the advent of 
FNAB, thyroid scintigraphy performed with Technetium Tc 99m pertechnetate (99mTc) or 
radioactive iodine (I131 or I123) was the initial diagnostic procedure [13]. Benign nodules 
appear as hot nodules in scintigraphy images because they are more frequently 
hyperfunctioning and have a high captation rate of radionuclide, and physiologically, 
iodine [13]. By contrast, malignant nodules usually appear as cold in scintigraphy images 
because, frequently,  they are not functioning [13]. However, this procedure is not as 
sensitive or specific as FNAB [13]. 
 
The diagnosis of papillary carcinoma is based on the nuclear morphology of the 
thyroid neoplasms [16]. By definition, PTC (Figure 3), has enlarged and elongated nuclei 
with crowding and overlap, irregular nuclear contour, chromatin clearing with peripheral 
margination of chromatin, giving rise to what has been described as Orphan Annie Eye 
nuclei; multiple micronucleoli located immediately underneath the nuclear membrane; 
nuclear grooves resulting from irregularity of nuclear contour; and intranuclear cytoplasmic 
pseudoinclusions from the accumulation of cytoplasm in prominent nuclear grooves [16]. 
Macroscopically, the lesions are firm and usually white in colour with an invasive 
appearance; lesional calcification is a common feature and cyst formation may be 
observed [17]. Microscopically, the neoplastic papillae contains a central core of 
fibrovascular tissue lined by one or several layers of cells with crowded oval nuclei [17].  
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Figure 3 – Papillary thyroid carcinoma histologic features (Schularick et al (2013) Pathology of papillary 
thyroid carcinoma, in Iowa Head and Neck protocols). 
 
About 90% of the DTC are effectively cured by surgery (total or partial 
thyroidectomy) followed, when adequate,  by RAI ablation therapy with 131 Iodine  [8] (131I 
is a β and γ emitting radionuclide and chemically identical to the non-radioactive form of 
iodine [7]). DTC of follicular origin retain, to varying degrees, the ability of normal 
thyrocytes to uptake and retain iodine [18]. The iodine trapping depends on the availability 
of NIS, which is an energy-dependent transport system regulated by the thyroid 
stimulating hormone (TSH) [7]. Since NIS is only present in thyroid follicular cells and 
DTCs, undifferentiated thyroid cancer and medullary thyroid cancer (parafollicular cell 
origin) are not responsive to RAI treatment [7]. In the absence of thyroid tissue (after 
surgical excision), serum thyroglobulin can be used as an excellent tumor marker for the 
detection of persistent or recurrent disease [19]. To achieve sufficient iodine uptake into 
tumor cells, RAI therapy requires high levels of TSH that can be achieved through thyroid 
hormone withdrawal or by injection of  human recombinant TSH [18]. 
 
Contrarily to the majority of DTC that have a good prognosis, in 10% of the cases 
of DTC patients are diagnosed in an advanced stage of the disease, with local invasion 
and/or distant metastases and curing these cases with surgery and RAI therapy might be 
unlikely since these tumors tend to have a very low avidity for iodine [20]. The same 
happens with ATC and PDTC, whose tumoral cells are so dedifferentiated that they are no 
longer able to express NIS and  uptake radioiodine; MTC, for biological reasons, a tumor 
derived from parafollicular C-cells, does not have ability to trap iodine [20]. For these 
cases, where there is not a rationale for using RAI therapy, there are other treatment 
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strategies. External beam radiation therapy (EBRT) and chemotherapy with cisplatin or 
doxorubicin can also be employed [13].  
In the last decade, the increased understanding of the molecular mechanisms 
underlying thyroid tumors (see below) allowed the development of targeted therapies. The 
mitogen activated protein kinase (MAPK) pathway is one of the most studied pathways in 
the thyroid pathology and there are several therapies, approved or in clinical trials, that 
target this pathway [8]. Cabozantinib and Vandetanib are tyrosine kinase inhibitors (TKI) 
approved for treatment of MTC [21]. Sorafenib is also a TKI that targets BRAF, RET, 
VEGFR, PDGFRA and c-KIT, approved for treatment of late-stage metastatic DTC [8].  
 
Papillary Thyroid Carcinoma histopathology and variants 
 
There are several variants of PTC. The classic variant is characterized by complex 
papillae with thin fibrovascular cores. The papillae are covered by cuboidal and columnar 
cells with eosinophilic cytoplasm; psamomma bodies can also be identified and present a 
characteristic purple colour with laminated calcification [16].  
The follicular variant of PTC presents a follicular architecture with nuclear features 
of papillary carcinoma. It is observed hypereosinophilia of colloid with peripheral 
scalloping, as well as, intrafollicular multinucleate giant cells and rare psamomma bodies 
[16]. Because these tumors can be confused with follicular adenomas and follicular 
carcinomas, the use of immunohistochemical and molecular markers are useful in the 
differential diagnosis [22]. 
The oncocytic variant is recognized by the presence of cells with abundant 
eosinophilic and granular cytoplasm as a consequence of mitochondrial accumulation. 
The cells can be arranged in classic papillae or in follicles, either with microfollicular ou 
macrofollicular architecture [16]. These tumors tend to have a distinct brown colour on 
gross examination [22].  
The clear cell variant presents a papillary architecture and cytological features of 
PTC constituted by clear cells [22]. It is related to the oncocytic variant and tumors with 
clear cells usually have oncocytic cells as well [16].  
The solid variant is characterized by unencapsulated and invasive borders. Cells 
are arranged in sheets intervened by fibrous stroma. Papillary formations are rare and the 
follicular pattern is partly maintained [16]. Vascular invasion and extrathyroidal extension 
are present in about a third of cases [22], that justifies the known aggressive behaviour of  
this variant, also associated with a high frequency of distant metastasis [16]. 
The tall cell variant is an uncommon and infiltrative tumor composed predominantly 
of cells whose length is at least 3 times their width. The cells usually have an abundant 
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eosinophilic cytoplasm and nuclear morphology that is typical of PTC [16]. These tumors 
tend to be larger than the classical PTC and necrosis, mitotic activity and extrathyroidal 
extensions are more frequently observed [22]. 
The columnar cell variant is a rare variant that is made up of pseudo stratified 
columnar cells. These cells may have supranuclear and subnuclear cytoplasmic vacuoles 
and some tumors may resemble endometrial or colonic adenocarcinomas [22]. This 
variant may be identical to the tall cell variant. The major difference is that tall cell variant 
has papillae that are delineated by a single layer of tall cells with an abundant eosinophilic 
cytoplasm and the presence of granules that give an oncocytic appearance [23]. 
The cribriform-morular variant is associated with familial adenomatous polyposis 
and Gardner Syndrome [22]. This variant is characterized by lobules of tumor separated 
by fibrous septa that have cribriform architecture characterized by rigid spaces in the 
lobules formed by arches of cells with no fibrovascular cores. Spindle cells and squamous 
morules can also be identified [16].  
The diffuse sclerosing variant is more frequent in young adults [17]. It is 
characterized by diffuse involvement of the thyroid and both lobes are typically involved. 
Papillary structures in dilated lymphovascular spaces are often present; the tumor shows 
extensive squamous metaplasia, abundant psamomma bodies, stromal fibrosis and 
prominent lymphocytic thyroiditis [22].  
Papillary microcarcinoma (mPTC) is defined as a papillary carcinoma that 
measures 1 cm or less in its maximum dimension [16]. These tumors are often found 
incidentally and are very common; the pattern of growth can be infiltrative or encapsulated; 
mPTC are frequently multiple (multifocal) [16]. mPTC incidence rates have been steadily 
increasing all over the world due to improvement of diagnostic methods [24]. In most of 
the cases, mPTC has a benign behaviour with an indolent course and excellent prognosis 
[24]. However, some have aggressive features and may require aggressive treatment [24]. 
The standard therapeutic approach for these tumors remains controversial. With the 
purpose of predicting those that will cause significant disease, many studies have been 
trying to associate poor prognostic markers with genetic alterations in this type of cancer. 
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EPIDEMIOLOGY 
 
Thyroid carcinoma is the most frequent endocrine neoplasia and accounts for 1% 
of all malignancies, having an incidence higher in women than in men (3 times more 
frequent) [25].  
The most frequent type of thyroid cancer is PTC (75-85%), followed by FTC (10-15%) and 
poorly differentiated/undifferentiated thyroid cancers (<5%) represent a minority of thyroid 
neoplasias [7, 26]. The overall 5 and 10-year survival rates of PTC are approximately 97% 
and 93%, respectively [7]. For FTC, the overall 5 and 10-year survival rates are 91% and 
85%, respectively [7]. ATC is uncommon and very lethal. Its mean survival time is usually 
less than 6 months from the time of diagnosis and this outcome is not altered by current 
treatments [7]. MTC (~4%) is more aggressive than follicular cell derived thyroid 
carcinoma, being responsible for 8% to 15% of all thyroid cancer-related deaths and with 
a 10-year survival rate of 75-85% [27, 28]. Thyroid cancers can occur at any age but the 
risk peak for women is between their 40s and 50s and for men between their 60s and 70s 
[25]. 
According to RORENO (Registo Oncológico Regional do Norte), the incidence of 
thyroid cancer in the north of Portugal is 15 cases per 100 000 individuals and it is the 
third most prevalent cancer in women (8.2% of all cancers in women with 23.9 cases per 
100 000 individuals) [29]. In Portugal, the overall mortality rate was 0,7 per 100 000 
individuals [30]. The 5-year survival rate is 97.9% (women with slightly increase when 
compared with men), being the cancer with the best survival rate in Portugal [31]. 
 
Thyroid cancer incidence has continuously increased in the last three decades all 
over the world [32]. The increase is nearly exclusively due to increases in the incidence of 
the papillary histotype and small tumors rather than large tumors [32]. In spite of the 
steadily increased incidence, thyroid cancer mortality is reported stable at approximately 
0.5 deaths per 100,000 persons [33]. Explanations for the worldwide increase of thyroid 
cancer incidence are controversial, with some experts believing that it is due to the 
increased diagnostic intensity [34]. In particular, the incidence rate in South Korea in 2011 
was 15 times higher than in 1993 [35]. This increase resulted when providers added 
thyroid screening with ultrasonography to other cancer-screening tests paid by the 
government [36]. When the screening was stopped the incidence of thyroid cancer started 
to decreased.  Overdiagnosis detects diseases that will not affect patient health and 
survival. Detecting these diseases not only will confer little benefit to the patient but may 
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also cause potential damage in terms of avoidable distress, possible adverse 
consequences of unnecessary treatment, and increasing economic cost [37]. 
Nevertheless, other experts believe that a true increase, due to environment and lifestyle 
changes, is also a possibility [32] [38]. 
  
Although the precise causes of thyroid cancer remain unclear, there are several 
observational studies that propose some factors that increase the risk of developing a 
thyroid cancer (TC), such as exposure to radiation, sex (women) and a diet low in iodine 
[25]. Radiation treatment of head and neck carcinomas and the exposure to radiation in 
Chernobyl accident have been two of the most studied risk factors for TC [39, 40]. In 2012, 
a meta-analysis of 7 cohort studies demonstrated the association of obesity and increased 
TC risk (by 18%) [41]. Diabetes mellitus have been also associated with increased TC risk 
[42-44]. Acromegaly, a rare syndrome that is caused by excess production of growth 
hormone, is highly associated with cancer risk, specifically TC [45-47]. Several studies 
propose that patients with benign thyroid diseases such as goiter, benign nodules, 
Hashimoto’s thyroiditis (autoimmune disease) and hyperthyroidism are also at high risk of 
developing TC [48-50]. Genetic susceptibility is also associated with the risk of developing 
TC. Some studies demonstrated that individuals with family history of TC have an 
increased risk of developing TC [51, 52]. More controversially, some studies, unlike the 
majority of cancers, suggested that cigarette smoking and alcohol consumption were 
associated with decreased risk of thyroid cancer [53]. A meta-analysis of 31 observational 
studies also concluded that the risk of thyroid cancer was decreased 21% in ever-smokers 
compared to never-smokers [54]. 
 
GENETIC ALTERATIONS 
 
PTC frequently has genetic alterations leading to the activation of the mitogen-
activated protein kinase (MAPK) signalling pathway (Figure 4). Those include B-Raf 
Proto-Oncogene, Serine/Threonine Kinase (BRAF) and RAS Viral Oncogene Homolog 
(RAS) point mutations and RET/PTC rearrangements. Mutations involving one of these 
genes are found in >70% of PTC and they rarely overlap in the same tumor [55]. Recently, 
mutations in telomerase reverse transcriptase (TERT) gene promoter were found in TC 
with an overall prevalence of near 10% [56] [57].   
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Figure 4 – Schematic representation of the MAPK signaling pathway. Physiologically, binding of growth 
factors to receptor TKs, results in receptor dimerization and activation via autophosphorylation of tyrosine 
residues in the intracellular domain. The activated receptor, through a series of adaptor proteins, leads to 
activation of RAS located at the inner face of the plasma membrane by substitution of GDP with GTP. The 
GTP-bound form of RAS binds to and recruits RAF proteins, mainly BRAF in thyroid follicular cells, to the 
plasma membrane. Activated BRAF is now able to phosphorylate and activate the MEK, which in turn 
phosphorylates and activates the ERK. Once activated, ERK phosphorylates cytoplasmic proteins and 
translocates into the nucleus, in which it regulates transcription of the genes involved in cell differentiation, 
proliferation, and survival. Alterations of this pathway in thyroid cancer can occur at different levels as a result 
of point mutations or rearrangement involving the RET, RAS and BRAF genes [2] (Ciampi et al. (2007) 
RET/PTC Rearrangements and BRAF mutations in thyroid tumorigenesis, Endocrinology). 
 
BRAF point mutations 
 
The BRAF gene on chromosome 7 (7q34) encodes the BRAF protein [58]. It 
belongs to the RAF protein family, being a serine-threonine protein kinase and a member 
of the RAS-RAF-MEK-ERK cell-signalling pathway (also known as the Mitogen Activated 
Protein Kinase (MAPK) pathway) [59]. This pathway regulates important cell functions 
including cellular growth, differentiation, proliferation, senescence and apoptosis [59]. 
BRAF phosphorylates and activates MEK, which in turn phosphorylates and  activates 
ERK and all the downstream effector molecules of the MAPK pathway [60]. Once 
activated, ERKs can be translocated into the nucleus where they phosphorylate 
transcription factors, regulating their activity [60]. The most common genetic alterations in 
PTC refers to point mutations of BRAF [7]. More than 95% of BRAF mutations detected in 
TC are thymine to adenine conversions at position 1799 (T1799A) at exon 15, resulting in 
the substitution of valine by glutamate at residue 600 (V600E) [61]. This mutation causes 
constitutive activation of BRAF kinase and, thus, activation of the MAPK signalling 
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pathway, which is relevant for thyroid tumorigenesis [62]. In its wild-type conformation, 
residues G597 to V601 form a hydrophobic interaction with residues G465 to V472 in the 
ATP-binding site, keeping it inactivated [63]. The BRAF V600E mutation disrupts the 
hydrophobic interaction, enabling the BRAF kinase to fold into a catalytically active 
formation, resulting in an almost 500-fold increase in kinase activity [63]. According to a 
recent meta-analysis, BRAF V600E mutation has an overall prevalence of 57% in mPTCs, 
being the most common genetic alteration in this type of tumors [64]. In small percentages 
of PTC, K601E point mutations, small deletions or insertions around codon 600 and 
AKAP9/BRAF rearrangement can also be observed [7].  
 
RAS point mutations 
 
The RAS gene encodes a family of three highly homologous genes: 
Neuroblastoma RAS Viral Oncogene Homolog (NRAS), Harvey Rat Sarcoma Viral 
Oncogene Homolog (HRAS) and Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS). 
These 21-kDa membrane-associated proteins play a central role in the transduction of 
signals from tyrosine kinase and G protein-coupled receptors to effectors of the MAPK 
and PI3K-AKT signalling pathways, that is, from cell membrane receptors to their 
intracellular effector molecules. [65]. RAS proteins exist as an active form with guanosine 
triphosphatase (GTPase) activity and an inactive form that is bound to guanosine 
diphosphate (GDP) [7]. Point mutations produce oncogenic alleles of RAS that exhibit 
either increased affinity for GTP (mutations in codons 12 and 13) or inhibition of 
autocatalytic GTPase function (mutation in codon 61) [65]. Both mechanisms result in 
constitutive, aberrant activation of the downstream MAPK and PI3K/AKT signalling 
pathways [65]. Most series demonstrate predominance of NRAS 61 (Q61R; c.182A>G) 
mutant isoform in thyroid neoplasms [65].  There are also increasing evidence that RAS-
positive PTC are mainly of the follicular variant subtype (FVPTC) [65]. According to a 
recent meta-analysis which evaluates this mutation in 106 tumors, the overall prevalence 
of RAS mutations in mPTCs is only 4% [64].  
 
RET/PTC Rearrangements 
 
Proto-oncogene RET (rearranged during transfection) encodes for a membrane-bound 
receptor tyrosine kinase and is highly expressed in calcitonin-producing parafollicular cells 
(C cells) in the thyroid gland [66]. RET gene is located on chromosome 10q11.2 [67] and 
contains three functional domains: an extracellular ligand-binding domain, a hydrophobic 
transmembrane domain and an intracellular tyrosine kinase domain [2]. In follicular cells it 
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can be activated by a chromosomal rearrangement know as RET/PTC rearrangement [68]. 
This rearrangement is characterized by a fusion of the 3’ portion of RET gene to the 5’ 
portion of several unrelated genes [2].  At least 12 different types of RET/PTC 
rearrangement have been identified [66]. The two most common are RET/PTC1 (formed 
by the fusion with H4 (D10S170) gene) and RET/PTC3 (formed by the fusion with NCOA4 
(ELE1) gene) [66]. In RET/PTC rearrangements, fusion with protein partners possessing 
protein-protein interaction motifs provides RET/PTC kinases with dimerizing interfaces, 
which results in ligand-independent autophosphorylation of the tyrosine kinase domain  
[66]. The loss of the transmembrane domain in the rearranged protein results in the 
cytoplasmic expression of the constitutively active fusion gene. A recent meta-analysis 
reported an overall prevalence of 44% in mPTC, being the second most common genetic 
alteration in this type of tumors [64]. 
 
TERT promoter mutations 
 
Telomeres are DNA-protein structures that protect chromosome ends which 
consist of arrays containing guanine-rich (G-rich) repeats (TTAGGG)n in vertebrates. 
These structures prevent the eventual loss of coding DNA due to the end replication 
problem, a limitation that causes telomere shortening within each cell division and leading, 
eventually, to cellular senescence or apoptosis [69]. Human adult somatic cells usually 
repress telomerase expression, although the enzyme continues to be expressed in 
proliferative cells (germ cells and tissue stem cells) [70].  
Human TERT gene encodes the catalytic subunit of telomerase that together with a RNA 
component, TERC, maintains genomic integrity by telomere elongation [71]. Reactivation 
of telomerase is present in up to 90% of human cancers, and it allows proliferative cancer 
cells to maintain telomere length [70]. Mutations in the coding region of telomerase are 
very rare in human cancer [72]. In 2013, mutations in the promoter of the telomerase gene 
were reported for the first time, in melanoma [73, 74]. In the same year, TERT promoter 
mutations were reported in thyroid (follicular cell-derived tumors) with an overall 
prevalence of 10% [57]. A recent meta-analysis reported an overall prevalence of 4,6% in 
mPTC [64]. TERT promoter mutations occur in two hotspot positions, located -124 and -
146 bp upstream from the ATG start site (-124 G>A and -146 G>A, C>T on the opposite 
strand) and confer enhanced TERT promoter activity, by putatively generating a novel 
consensus binding site (GGAA) for E-twenty six transformation-specific (ETS)  
transcription factors family within the TERT promoter region [57, 73, 74]. 
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AIMS OF THE STUDY 
 
 
The general aim of this work was to evaluate the mPTC genetic profile. In order to 
do that, we intended to evaluate the prevalence of BRAF (exon 15, codon 600 region), 
NRAS (exon 3, codon 61 region) and TERT promoter mutations in a series of mPTC.  
We also intended to investigate possible associations of those genetic alterations 
with classical clinicopathological features. 
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MATERIALS AND METHODS 
Samples 
All the procedures described in this study were performed according to national 
ethical rules and with the approval of the ethic committee of Centro Hospitalar de São 
João (CHSJ).  
Tumor samples were obtained from CHSJ between 1996 and 2013 and were 
stored as formalin-fixed paraffin-embedded (FFPE) tissue samples. Diagnosis and 
clinicopathological data were obtained by a pathologist and endocrinologist, both from 
CHSJ. This series included 113 patients and was selected according to outcome, 
specifically a worse outcome when compared to the majority of mPTC. Some cases are 
composed of more than one sample, as mPTC has frequently multifocality. Unfortunately, 
it was not possible to analyse all 113 patients due to lack of time. 
The clinicopathological variables studied were gender, age, age at diagnosis, initial 
diagnosis, tumor size, histologic architecture variant, tumor localization in thyroid (left lobe, 
right lobe, isthmus, diffuse and pyramidal lobe), localization (central or peripheral), 
presence of thyroiditis (yes or no), vascular invasion (yes, suggestive or no), capsular 
invasion (yes or no), extrathyroidal invasion (yes, suggestive or no), presence of 
psammoma bodies (yes or no), lymph node metastasis (yes or no), multifocality (yes or 
no), tumor capsule (yes or no), tumor capsular invasion (yes or no), growth pattern 
(infiltrative, expansive or mixed), tumor margins (well defined or poorly defined), presence 
of necrosis (yes or no), intratumoral inflammatory infiltration (none, lymphocytic-scarce or 
lymphocytic), local metastasis (no or lymph node), number of lymph node metastasis, 
histologic relapse (yes or no) and years to relapse. 
 
DNA extraction 
Tumor areas were delimited, by a pathologist, in the haematoxylin and eosin (H&E) 
stained slides of each sample. The corresponding unstained slides were used for DNA 
extraction. The paraffin from FFPE slides was removed by immersion in xylene (Atom 
Scientific Ltd, United Kingdom) for 2 x 10 minutes and 2 x 5 minutes in ethanol 100% (Aga 
– Álcool e Géneros Alimentares, S.A., Portugal). Tumor areas, which were previously 
delimited by comparison with respective H&E slides, were macrodissected and transferred 
to a microcentrifuge tube. DNA was isolated using the GRS genomic DNA kit (GRiSP®, 
Portugal) and according to manufacturer’s instructions. Finally, DNA was quantified by 
Nanodrop N-1000 Spectrophotometer (Thermo Scientific®, USA) and stored at 4 ºC.  
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Genetic alterations 
 
Polymerase chain reaction (PCR) was performed using QIAGEN® Multiplex PCR 
kit in a final volume of 14 µl. This final mixture was composed of 6,25 µl of 2x QIAGEN 
PCR Master Mix (QIAGEN); 1,25 µl of Q-solution, 5x (QIAGEN); 3,5 µl of DNase and 
RNase free water; 0,25 µl each primer 100 uM (forward and reverse) and 2,5 µl of DNA 
template. PCR reaction was run in MyCycler™ thermal cycler (BIO RAD®, USA). The 
temperature conditions of PCR reaction consisted in an initial denaturation at 95ºC for 15 
minutes, followed by 40 cycles with denaturation at 95ºC for 30 seconds, annealing of 
primers at 61ºC for 90 seconds and polymerase extension at 72ºC for 1 minute. After the 
40 cycles the samples were subjected to a final extension at 72ºC for 10 minutes. In all 
PCR reactions it was used negative controls differing from the normal samples only by not 
having DNA template.  
To confirm the efficiency of the PCR reaction, the products were run in a 2% 
agarose gel electrophoresis, using the SGTB 1x buffer (ref. GB01.0520, GRiSP, Portugal). 
The samples were mixed with 1μL of Loading Buffer with Gel Red® Nucleic Acid Gel 
Stain 3X (ref. 41003, Biotium, Inc, USA), where the loading buffer provides density to the 
sample and include colored dyes used to monitor the progress of the electrophoresis and 
the Gel Red® intercalate into the major grooves of the DNA and will be fluorescent under 
UV light, according to the manufacturer guidelines. To evaluate the size of the PCR 
products in the electrophoresis gel, 1kb Plus DNA Ladder (ref 10787-026, Invitrogen, USA) 
was used. The gel was analysed in ChemiDoc™ XRS Imaging System, BIORAD in an UV 
filter lamp (Model: Universal Hood II, Hercules, CA, USA - 50/60 Hz). 
Before sequencing, all PCR products were purified to remove excess of primers, 
salts, dNTPs and enzymes from the PCR reaction, using the ExoSap method. ExoSap is 
composed by two hydrolytic enzymes, Exonuclease I 20U/μL (ref. #ENO582, Thermo 
Scientific) and Shrimp Alkaline Phosphatase (Fast AP Thermosensitive Alkaline 
Phosphatase 1U/μL, ref. #EF0651, Thermo Scientifics). For that purpose, it was added 
1,5 µl of ExoSap to the PCR product, followed by incubation at 37ºC for 30 minutes, 
optimal temperature for the enzymes action, and 80 ºC for 15 minutes for their inactivation. 
The PCR products were analysed by DNA sequencing (Sanger sequencing) using 
ABI Prism BigDye Terminator Kit v3.1 Cycle Sequencing (ref 4337455, Applied 
Biosystems®, United Kingdom). The final mixture had 2,5 µl of PCR product, 0,25 µl of 
BigDye, 3,4 µl of Sequencing buffer (Big Dye® Terminator v1.1, v1.3 5x sequencing buffer, 
ref 4336697, Applied Biosystems®), 0,3 µl of one of the primers (forward or reverse) and 
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3,4 µl of DNase and RNase free water. The final mixture was amplified in MyCycler™ 
thermal cycler (BIO RAD®) with an annealing temperature of 55ºC. 
PCR sequencing products were purified using Zetadex-50 Superfine Gel Filtration 
Matrix (ref. TM-0104-E100.0-001, Biotech GmbH, Germany) columns to remove all 
ddNTPs not incorporated during sequencing reaction. After this step, it was added 15 µl of 
Hi-DiTM Formamide (ref 1403305, Applied Byosystems®) to the samples. Finally, samples 
were run in an ABI prism 3100 Genetic Analyzer (Perkin-Elmer, USA). Electropherograms 
of each sample were analysed with the Sequencing Analysis Software v5.4 (Applied 
Biosystems).  
All positive cases for mutation were validated by a new independent analysis (this 
independent analysis was not performed as no positive cases for mutation were obtained). 
 
Statistical analysis 
 Statistical analysis was performed using IBM SPSS Statistics version 24 (IBM, 
USA).  
 For the analysis of relationship between the continuous variables tumor size and 
age with clinicopathological characteristics, unpaired t-test and variance analysis was 
used. Chi-square test was used, with Fisher’s correction when eligible, for analysis of 
relationship between the other clinicopathological characteristics. Frequency tables for 
each of the variables, expressed in frequency and percentage were also obtained. We 
considered statistically significant P-value<0.05. 
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RESULTS 
 
This series included a total of 113 patients with the diagnosis of mPTC. A total of 
66 DNA slides from 45 patients were analysed for molecular characterization. 
It was our intention to classify molecularly these tumors, analysing the prevalence 
of BRAF, NRAS and TERT promoter mutations. However, only the analysis of NRAS 
mutations was successful.  
Of the 45 patients, the mean age was 50, ranging from 21 to 77 years. The 
majority of the patients were older than 45 years (66.7%). There were a total of 3 male 
cases (6.7%), with a mean age of 57 (41-75) years, and 42 female cases (93.3%), with a 
mean age of 50 (21-77) years. 
Of the 45 patients, 13 (28.9%) were incidental cases, which means that the 
microcarcinoma was not diagnosed per se but during pathologic examination of thyroid 
specimens after surgery for benign thyroid diseases or other malignant diseases (follicular 
thyroid tumor, papillary thyroid tumor and hurthle cell thyroid tumor).  
In the 45 patients, 81 mPTCs were diagnosed. 21 patients (46.7%) had only 1 
microcarcinoma and the remaining 24 (53.3%) patients had multifocality. Multifocality had 
the same number of unilateral and bilateral cases. Within the 24 cases with multifocality, 
16 (66.7%) presented equal histotype architecture variant among all the microcarcinomas 
of the same case. Regarding the number of lesions in the cases presenting multifocality 
18 patients (40.0%) had 2 microcarcinomas, 2 patients (4.4%) had 3 microcarcinomas, 2 
patients (4.4%) 4 microcarcinomas and 2 (4.4%) patients presented 5 microcarcinomas. 
Tumors presented a maximum of 10 millimetres (mm) and a minimum of 1 mm in their 
maximum diameter, with a mean maximum diameter of 5.5 mm.  
From the 81 mPTCs, 44 (54.3%) had follicular architecture, 25 (30.9%) classical 
architecture, 9 (11.1%) mixed architecture (half follicular and half classical) and 3 (3.7%) 
solid architecture – Table 1. 42 (51.9%) mPTCs were located in the right lobe, 38 (46.9%) 
in the left lobe and 1 (1.2%) in the pyramidal lobe.  
 
Table 1 – Diagnosis of the architecture of the papillary thyroid microcarcinoma 
Predominant 
architecture diagnosis 
Frequency (n=81) Percentage (%) 
Follicular  44 54.3 
Classical 25 30.9 
Mixed  9 11.1 
Solid  3 3.7 
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Of the 45 patients, 4 (8.9%) had tumor encapsulation and of those 4 all (100%) 
had invasion of the capsule. Furthermore, 21 (46.7%) patients had vascular invasion 
(cases with suggestive vascular invasion were included), 33 (73.3%) had extrathyroidal 
invasion (cases with suggestive extrathyroidal invasion were included) and 19 (42.2%) of 
the patients had tumor lymphocytic infiltrate (cases with scarce tumor lymphocytic infiltrate 
were included). The majority of the patients had an infiltrative tumor growth pattern 
(82.2%), poorly defined tumor margins (93.3%) and had no lymph node metastasis 
(91.1%). Only 2 patients (4.4%) had histologic relapse, which means that their relapse 
was confirmed by histologic analysis. 10 (22.2%) patients had Multinodular Goiter (MNG) 
and 16 (35.5%) colloid nodules. In 11 (24.4%) patients psammoma bodies were found – 
Table 2. 
 
Table 2 – Pathological and molecular characteristics of the mPTCs in the 45 patients 
Variables Frequency (n=45) Percentage (%) 
Age 
<45 years 15 33.3 
≥45 years 30 66.7 
Gender 
Male 3 6.7 
Female 42 93.3 
Incidental mPTC 13 28.9 
Multifocality 
No 21 46.7 
Yes 24 53.3 
Multifocality 
side 
Unilateral 12 50.0 
Bilateral 12 50.0 
MNG 10 22.2 
Colloid nodules 16 35.5 
Psammoma bodies 11 24.4 
Tumor capsule 4 8.9 
Tumor capsule invasion 4 8.9 
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Vascular invasion  
(cases with suggestive 
vascular invasion were 
included) 
 
21 46.7 
Extrathyroidal invasion 
(cases with suggestive 
extrathyroidal invasion were 
included) 
33  73.3 
Lymphocytic infiltrate 19  42.2 
Tumor 
margins 
Well-
defined 
3 6.7 
Poorly-
defined 
42 93.3 
Growth 
pattern 
infiltrative 37 82.2 
expansive 3 6.7 
mixed 5 11.1 
Lymph node metastasis 4 8.9 
Histologic relapse 2 4.4 
NRAS mutation 0 0 
 
We also did a comparative analysis between the 2 most prevalent mPTC 
architecture variants present in this series, classical (c-mPTC) and follicular (fv-mPTC), to 
see the distribution of the clinicopathological characteristics in those variants.– Table 3. 
Of the 45 patients, 13 were diagnosed with c-mPTC (single or multiple) with a 
mean age of 47 years and 20 with fv-mPTC (single or multiple) with a mean age of 51 
years. 
 
Table 3 – Pathological and molecular characteristics of c-mPTC and fv-mPTC. 
Variables 
c-mPTC  
(n=13) 
fv-mPTC  
(n=20)  
Age 
(%) 
<45 years 
4 
(30.8) 
8 
(40.0) 
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≥45 years 
9 
(69.2) 
12 
(60.0) 
Gender 
(%) 
Male 
1 
(7.7) 
2 
(10.0) 
Female 
12 
(92.3) 
18 
(90.0) 
Incidental mPTC 
(%) 
3 
(23.1) 
8 
(40.0) 
Multifocality 
(%) 
No 
8 
(61.5) 
10 
(50.0) 
Yes 
5 
(38.5) 
10 
(50.0) 
Tumor capsule 
(%) 
1 
(7.7) 
1 
(5.0) 
Tumor capsule invasion 
(%) 
1 
(7.7) 
1 
(5.0) 
Vascular invasion (cases with 
suggestive vascular invasion were 
included) 
(%) 
7  
(53.9) 
9 
(45) 
Extrathyroidal invasion (cases with 
suggestive extrathyroidal invasion were 
included) 
(%) 
6  
(46.2) 
17 
(85.0) 
Lymphocytic infiltrate (cases with 
scarce tumor lymphocytic infiltrate were 
included) 
(%) 
6 
(46.2) 
11 
(55.0) 
Tumor margins 
(%) 
 
Well-
defined 
1 
(7.7) 
1 
(5.0) 
Poorly-
defined 
12 
(92.3) 
19 
(95.0) 
Growth pattern 
(%) 
infiltrative 
7 
(53.8) 
19 
(95.0) 
expansive 
2 
(15.4) 
1 
(5) 
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mixed 
4 
(30.8) 
0 
(0) 
Lymph node metastasis 
(%) 
2 
(15.4) 
1 
(5) 
Histologic relapse 
(%) 
1 
(7.7) 
0 
(0) 
NRAS mutation 
(%) 
0 
(0) 
0 
(0) 
 
 
When the two most prevalent variants were compared, c-mPTC and fv-mPTC, 
statistical significant differences were observed. The c-mPTC group had more psammoma 
bodies (53.8% vs 15.0%) and less extrathyroidal invasion (41.7% vs 85.0%) when 
compared with the fv-mPTC group – Table 4. 
 
Table 4 – Comparison between the classical mPTC and follicular variant mPTC, in relation to the 
variables extrathyroidal invasion and psammoma bodies. 
Variables 
Variant diagnosis 
p-value 
c-mPTC fv-mPTC 
Extrathyroidal 
invasion 
(%) 
Yes 
5 
(41.7) 
17 
(85.0) 
0.018 
No 
7 
(58.3) 
3 
(15.0) 
Psammmoma 
bodies 
(%) 
Yes 
7 
(53.8) 
3 
(15.0) 
0.026 
No 
6 
(46.2) 
17 
(85.0) 
 
When the incidental cases of mPTC were compared with the non-incidental cases, 
it was possible to report statistical significant differences with the incidental cases being  
more frequentely associated with colloid nodules (76.9% vs 18.8%) and with multinodular 
goiter (MNG) (61.5% vs 6.3%) when compared with the non-incidental cases of mPTC. It 
is also possible to report a larger mean maximum diameter (mean of all tumors of each 
case) in the group of the non-incidental cases – Table 5. 
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Table 5 – Comparison between the incidental and non-incidental cases of mPTC, in relation to the 
variables colloid nodules, multinodular goiter (MNG) and mean maximum diameter of all tumors of the 
case. 
Variables 
Incidental mPTC 
p-value 
Yes No 
Colloid 
nodules (%) 
Yes 
10 
(76.9) 
6 
 (18.8) 
0.000 
No 
3 
(23.1) 
26 
(81.3) 
MNG 
(%) 
Yes 
8 
(61.5) 
2 
(6.3) 
0.000 
No 
5 
(38.5) 
30 
(93.8) 
Mean tumor size (mm) 5.12 6.57 0.033 
 
When the cases with and without multifocality were compared, it was possible to 
report a tendency, with the cases with multifocality being more frequent in females (100% 
vs 85.7%), having less lymph node metastasis (0% vs 19.0%)  and  the tumor margins 
being frequently poorly-defined (100% vs 85.7%) when compared with the cases without 
multifocality  – Table 6. 
 
Table 6 – Comparison between the cases with and without multifocality, in relation to the variables 
gender, lymph node metastasis and tumor margins 
Variables 
Multifocality 
p-value 
Yes No 
Gender 
(%) 
Male 
0 
(0) 
3 
(14.3) 
0.094 
Female 
24 
(100) 
18 
(85.7) 
Lymph node 
metastasis 
(%) 
Yes 
0 
(0) 
4 
(19.0) 
0.040 
No 
24 
(100) 
17 
(81.0) 
Tumor 
margins 
(%) 
Well-
defined 
0 
(0) 
3 
(14.3) 
0.094 
Poorly-
defined 
24 
(100) 
18 
(85.7) 
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When the group with and without lymph node metastasis were compared, it was 
possible to report statistical significant differences. The group with lymph node metastasis 
had more psammoma bodies (75.0% vs 19.5%) and less multifocality (0% vs 58.5%) 
when compared with the group without lymph node metastasis – Table 7. 
 
Table 7 – Comparison between the group with and without lymph node metastasis, in relation to the 
variables psammoma bodies and multifocality 
Variables 
Lymph node metastasis 
p-value 
Yes No 
Psammoma 
bodies (%) 
Yes 
3 
(75.0) 
8 
(19.5) 
0.040 
No 
1 
(25.0) 
33 
(80.5) 
Multifocality 
(%) 
Yes 
0 
(0) 
24 
(58.5) 
0.040 
No 
4 
(100) 
17 
(41.5) 
 
 When the group with and without tumor capsule were compared, it was possible to 
report some statistical significant differences, with the group with tumor capsule having all 
invasion of the tumor capsule (100 % vs 0%) and more well-defined tumor margins (50.0 
% vs 2.4%) when compared with the group with no tumor capsule. However, the group 
with tumor capsule had less poorly-defined tumor margins (50.0% vs 97.6%) – Table 8. 
 
Table 8 – Comparison between the group with and without tumor capsule, in relation to the variables 
Tumor capsule invasion and tumor margins. 
Variables 
Tumor capsule 
p-value 
Yes No 
Tumor 
capsule 
invasion 
(%) 
Yes 
4 
(100) 
 
0.000 
No 
0 
(0) 
 
Tumor Well- 2 1 0.018 
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margins 
(%) 
defined (50) (2.4) 
Poorly-
defined 
2 
(50) 
40 
(97.6) 
 
 When the group with tumors with a maximum diameter of less than 5 mm was 
compared with the group with at least one tumor with 5 mm or more, it was possible to 
report a tendency, although the difference is not statistically significant. 75.0% of the 
cases belonging to the group with at least one tumor with 5 mm or more are non-
incidental cases and 60.0% of the cases with a maximum diameter inferior to 5 mm are 
incidental cases – Table 9. 
 
Table 9 – Comparison between the group with tumors with maximum diameter inferior to 5 mm and 
the group with at least one tumor with maximum diameter of 5 mm or more, in relation to the variable 
Incidental mPTC. 
Variables 
Tumor size 
p-value 
<5 ≥5 
Incidental 
mPTC  
(%) 
Yes 
3 
(60.0) 
10 
(25.0) 
0.136 
No 
2 
(40.0) 
30 
(75.0) 
 
The 66 genotyped samples, from the 45 patients, analysed for the NRAS 
mutations were all (100%) wild-type, which included 63 tumor samples and 3 lymph node 
metastasis - Figure 5 and 6. 
 
 
Figure 5 – Representative results of an agaroses gel electrophoresis for the PCR of NRAS codon 61 
region, with a size of about 119 basepairs (1-DNA ladder; 2 & 3-negative control; 5 to 11-Positive case 
for amplification of NRAS. 
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Figure 6 – Wild-type representative results obtained through sequencing analysis of NRAS codon 61 
(bounded by 2 red lines) region, primer forward. 
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DISCUSSION 
 
Papillary thyroid microcarcinoma (mPTC) constitutes a topic of intense debate in 
endocrine oncology, as these cancers have a spectrum of behaviour that ranges from 
incidentally detected and clinically indolent tumours, a minority that behave more 
aggressively and a few that can become virtually untreatable neoplasms [24]. The 
importance of genetic characterization of mPTC is to obtain tools that can predict those 
that will cause significant disease. In this work we intend to evaluate the genetic profile of 
a series of mPTC from the North of Portugal, evaluating the prevalence of BRAF V600E, 
RAS and TERT promoter mutations. We also evaluated a number of clinicopathological 
features.  
In this study we have access to a series of mPTC that were selected based in the 
behaviour of the disease. The series is mainly composed of “worse” prognosis cases i.e.  
cases that, at presentation or in the follow-up period, showed vascular invasion, 
extrathyroidal invasion, metastasis or histologic relapse.   
We will start with the analysis of the clinicopathological characteristics of the 45 
mPTC cases included in in our study  [24].  
In this work, the female cases represented 93.3% of all cases. A recent meta-
analysis, addressing 75 studies, estimates that 82% of mPTC belong to women [24]. The 
reason(s) underlying the higher incidence of mPTCs and PTCs in women remains not 
explained. Some authors advanced the fact that estrogen is a potent growth factor for 
malignant thyroid cells [75]. In fact, it was demonstrated that estrogen has the ability to 
activate MAPK and PI3K signalling pathways, two pathways with major roles in thyroid 
oncogenesis [75-78].  
Multifocality is a common feature of mPTC and was also observed in this work. 
According to a recently published meta-analysis (2016) addressing 57 studies, 
multifocality prevalence in mPTCs is 28.0%. The multifocality prevalence of the series in 
this work was 53.0%. There are some studies that correlate the presence of multifocality 
with worse clinicopathological features, and that can be a possible explanation for the 
higher incidence of multifocality in this series. In fact, a recent work states that 
multifocality is an important factor for predicting tumor recurrence in mPTC [79]. Another 
study reports a higher capsular invasion, extrathyroidal invasion and lymph node 
metastasis in multifocal PTCs [80]. Interestingly, it was also reported an increase of these 
worse clinicopathological features in multifocal tumors that have a tumor diameter of less 
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than 10 mm, mPTCs, comparing with unifocal tumors with more than 10 mm [80]. 
Contrary to what a recent meta-analysis reports, in our results lymph node metastasis was 
more prevalent in unifocal tumors, with all four lymph node metastasis cases belonging to 
cases without multifocality [81]. Obviously, the numbers are too scarce to allow any 
meaningful tendency.  
mPTC are tumors frequently found during histopathological examination of the 
thyroid glands removed during necropsy or surgery for nonmalignant thyroid disease, 
which makes them incidental tumors [24]. A meta-analysis of 25 studies reports that 57% 
of mPTC are diagnosed incidentally. [24]. The fact that the mPTC series used in this work 
had only 28.9% of incidental cases can be associated to the fact that this is a series with 
aggressive features. Probably, most of the patients of this series had some symptoms and 
their mPTCs were diagnosed on clinical grounds, being non-incidental. This is confirmed 
by the observation that in the non-incidental cases 81.3% did not present colloid nodules 
and 93.8% did not have MNG (Table 5). It is also interesting to see that the non-incidental 
cases have a maximum diameter superior to the incidental cases, which is in accordance 
to the findings of a recent work that compared incidental with non-incidental mPTC and 
observed larger tumors in the non-incidental group [82]. 
When we compare cases with and without lymph node metastasis, it is interesting 
to see that 75.0% of the cases with lymph node metastasis had psammoma bodies and 
that 80.5% of the cases with no lymph node metastasis did not present psammoma 
bodies, showing that psamomma bodies are almost exclusive of cases with lymph node 
metastasis. A study that analysed 258 PTCs found that the presence of psammoma 
bodies was significantly correlated with lymph node metastasis [83]. It is also interesting to 
see that classical variant presents more frequently psammoma bodies (table 4). There is 
some evidence that psammoma bodies are much more prevalent in classical mPTC [23]. 
When we compare the prevalence of the different mPTC variants it is possible to 
report a higher prevalence of the follicular variant, 54.3%, comparing with 30.9% of the 
classical variant and a minority of the other two variants. The same meta-analysis 
reported before, accounts that classical variant is the most prevalent, with 71.0% and 
follicular variant the second most prevalent with 19.0% [24]. A recent study of 1990 cases 
that evaluated the outcome of mPTC, found an association between lymph node 
metastasis and follicular variant [84]. This finding suggests that this variant might be more 
aggressive and that can be a possible explanation for the higher prevalence of follicular 
variant in the series used in this work. The hypothesis that follicular variant is more 
aggressive was supported by the higher prevalence of extrathyroidal invasion in this 
variant when compared with classical variant (table 4).  
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The series included a total of 113 patients with the diagnosis of mPTC. 
Unfortunately, it was not possible to do the molecular analysis of all of them in time, as the 
molecular characterization was dependent on the analysed slides sent by the pathologist 
and the pathological features were also dependent on the pathologist’s analysis. For this 
reason only 45 cases were available for the molecular analysis. 
Although it was initially planned to analyse BRAF (exon 15, codon 600 region), 
TERT promoter and NRAS (exon 3, codon 61 region) mutations, only NRAS mutation 
analysis was successfully performed 
The TERT promoter sequence proved to be very difficult to amplify, as it is a gene 
promoter and it is known its high GC rich content. We failed to molecularly characterize 
TERT promoter in time for inclusion in this thesis. Since this sequence has successfully 
been genotyped in the past, in the research group were this work took place, it made us 
question about possible explanations for this problem. Due to the small size of 
microcarcinomas, the amount of DNA extracted from mPTC tissues was reduced, that 
could in part explain the increased difficulty in genotyping this sequence, although, 
previous mPTC have been studied in the group with similar amounts of material. Only two 
published studies report the analysis of TERT promoter mutations in mPTC, with an 
overall prevalence of 4.6%, ranging from 0%[57] to 4.7%[85]. One of these studies 
searched for associations between this mutation and unfavorable clinical features and 
nothing was found to be correlated [85]. This contrasts with the association found between 
TERT promoter mutations and worse outcome and disease-specific mortality in PTC [86]. 
Contrarily to TERT genotyping, BRAF amplification was successfully obtained. 
However, these results failed to be validated in a reliable way and therefore this data 
could not be used in order to not introduce biased or false results. BRAF V600E mutation 
is the most studied genetic alteration in mPTC and according to a recent-meta-analysis it 
has an overall prevalence of 57% (ranging from 0% to 90.7%) [64]. This prevalence is 
very similar to the 51% (ranging from 27.3% to 87.1%), reported in another recent meta-
analysis of 30 studies on PTC [87]. Many studies found association between BRAF 
mutation and some clinicopathological features predictive of tumor aggressiveness [85, 
88-102]. 
The fact that the sequence amplified of NRAS presented about 119 base pairs (bp) 
and the other two, BRAF and TERT promoter, have near 200 base pairs might explain the 
efficiency of this amplification, as a smaller sequence is more easily amplified. So, we did 
not face major complications in genotyping NRAS. 
  In this work, the prevalence of NRAS was 0% in the tumors and lymph node 
metastasis analysed. So far, there are only 4 published studies reporting the analysis of 
RAS mutations in mPTCs, with an overall prevalence of 3,8% (4/106), ranging from 0 to 
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5% [64, 103-106]. Interestingly, one of the studies that found RAS mutations stratified the 
series in two groups and reported no RAS mutations in the aggressive group, with all 
mutations belonging to the non-aggressive group [104]. This is an interesting result, as the 
analysis presented in this thesis was also done in an aggressive mPTC series and raises 
the question if aggressive mPTCs could have a lower frequency of RAS mutations. 
However, the absence of gene mutations precluded the search for associations of RAS 
with clinicopathological features of the mPTC. The general low prevalence of this mutation 
in mPTC contrasts with the observed frequency in normal PTCs that usually tend to affect 
10% of the cases studied, with follicular variants presenting an higher incidence [7].  
Genetic alterations of mPTC and the study of their association with 
clinicopathological features are of major importance to predict those cases that will cause 
significant disease. This series is composed by aggressive cases of mPTC. Their genetic 
characterization, when finished, will be an important tool for better understanding these 
uncommon cases with aggressive behavior. 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 Although the cases present in this series were selected based on their aggressive 
features, we confirmed the indolent clinical course of this type of tumor, with only 8.9% of 
lymph node metastasis and no distant metastasis or disease-specific mortality.  It was 
also possible to see a high number of multifocal, incidental and female cases, as expected. 
Interestingly, follicular architecture was predominant in this series and that can be related 
with the aggressive features of these cases. Furthermore, the genetic characterization of 
this series revealed no mutations in NRAS gene. The work presented on this thesis is still 
part of an ongoing work with more cases to be analysed for genetic alterations in BRAF, 
NRAS and TERT promoter. The results arising from this future analysis are of major 
importance for better understanding the relationship between genetic alterations and 
clinical outcome in this type of tumors. It remains to be found a marker that could 
distinguish which of these mPTC will indeed present a worse prognosis and will require a 
more radical approach in order to treat them. Additional, as observed in some countries, 
the increased detection of these small lesions represents an economic burden. Therefore, 
we aim to identify those that will cause significant disease so an aggressive therapeutic 
approach can be taken. 
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